Shandong Boan Biotechnology Co., Ltd. (6955.HK) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. 6955.HK files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 36.94% | 30.00% | Fail |
| Interest-bearing investments | 53.31% | 30.00% | Fail |
| Non-permissible income | 0.57% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 18.99% | 33.00% | Pass |
| Interest-bearing investments | 27.40% | 33.00% | Pass |
| Non-liquid assets | 56.93% | at least 20.00% | Pass |
| Non-permissible income | 0.57% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 18.99% | 33.33% | Pass |
| Cash + interest-bearing securities | 27.40% | 33.33% | Pass |
| Accounts receivable | 43.07% | 33.33% | Fail |
| Non-permissible income | 0.57% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 18.99% | 33.33% | Pass |
| Cash + interest-bearing securities | 27.40% | 33.33% | Pass |
| Accounts receivable | 43.07% | 50.00% | Pass |
| Non-permissible income | 0.57% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 12.85% | 33.00% | Pass |
| Cash + interest-bearing securities | 18.55% | 33.00% | Pass |
| Accounts receivable | 10.61% | 33.00% | Pass |
| Non-permissible income | 0.57% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 11.96% | 33.00% | Pass |
| Cash + interest-bearing securities | 17.26% | 49.00% | Pass |
| Accounts receivable | 9.87% | 49.00% | Pass |
| Non-permissible income | 0.57% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 11.96% | 33.33% | Pass |
| Cash + interest-bearing securities | 17.26% | 33.33% | Pass |
| Accounts receivable | 27.13% | 49.00% | Pass |
| Non-permissible income | 0.57% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 14.10 | BUY |
| Stochastic %K (14) | 10.79 | BUY |
| CCI (20) | -148.40 | BUY |
| Williams %R (14) | -89.21 | BUY |
| MACD (12,26,9) | -0.08 | SELL |
| ROC (10) | -24.60 | SELL |
| Momentum (10) | -0.92 | SELL |
| EMA (10) | 3.29 | SELL |
| SMA (10) | 3.33 | SELL |
| EMA (20) | 3.65 | SELL |
| SMA (20) | 3.76 | SELL |
| EMA (30) | 3.90 | SELL |
| SMA (30) | 4.06 | SELL |
| EMA (50) | 4.28 | SELL |
| SMA (50) | 4.43 | SELL |
| EMA (100) | 5.12 | SELL |
| SMA (100) | 5.11 | SELL |
| EMA (200) | 6.90 | SELL |
| SMA (200) | 6.69 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, and hepatocellular carcinoma indications; Boyoubei (BA6101), a human immunoglobulin G2 monoclonal antibody of the RANK ligand for the treatment of postmenopausal and male osteoporosis; and Boluojia (BA1102), a fully human IgG2 anti-RANKL monoclonal antibody to treat bone metastases from solid tumors, and giant cell tumor of bone. It also develops BA5101, a long-acting glucagon-like peptide-1 receptor agonist intended for glycemic control in adults with type 2 diabetes; BA9101, a recombinant human vascular endothelial growth factor receptor antibody fusion protein ophthalmic injection; BA1104, a monoclonal antibody in Phase 3 clinical trial that can enhance the immune response of T cells against tumors by preventing the programmed cell death 1 receptor; BA2101, a long-acting human monoclonal antibody of the IgG4 subtype in Phase 1b/2 trial that targets interleukin-4 receptor subunit a; BA1106, a non-IL-2 blocking anti-CD25 antibody in Phase 1b/2 trial; BA1301, an ADC candidate in Phase 1b/2 trial that targets Claudin 18.2; BA1202, a bi-specific antibody drug in Phase 1a trial that targets CEA/CD3; and BA1302, a CD228-directed ADC in Phase 1a trial. It has an agreement with the Zencore Biologics Co., Ltd. to use its stable cell line development platform non-exclusively, BA-HIEXcell for the development of antibodies and therapeutic proteins. The company was founded in 2013 and is headquartered in Yantai, China. Shandong Boan Biotechnology Co., Ltd. is a subsidiary of Shandong Luye Pharmaceutical Co., Ltd.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.